We really need to look into the story behind this Y-to -Y 15% sale drop, the whole quarter is under full impact of FDA new labeling request and many speculative legal actions from the lawyers.
The sale figure is not that bad considering all of these factors.
Important: Axiron' market share is still consistent.
We really need to look into the story behind this Y-to -Y 15%...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.7¢ |
Change
-0.002(4.08%) |
Mkt cap ! $13.66M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 4.9¢ | 4.6¢ | $15.47K | 324.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 154451 | 4.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 120000 | 1 |
View Market Depth
| Last trade - 15.17pm 11/11/2024 (20 minute delay) ? |
| ACR (ASX) Chart |